Summary
We have studied the effects of quinidine on ECG intervals and on the pharmacokinetics of flecainide and its two metabolites in 6 healthy men in an open randomized crossover study. Flecainide acetate (150 mg) was given as a constant rate i. v. infusion over 30 min.
Quinidine (50 mg orally), given the previous evening, did not change the volume of distribution of flecainide (7.9 vs 7.41·kg−1), but significantly increased its half-life (8.8 vs 10.7 h). This was attributable to a reduction in total clearance (10.6 vs 8.1 ml·min−1·kg−1), most of it being accounted for by a reduction in non-renal clearance (7.2 vs 5.2 ml·min−1·kg−1). The excretion of the metabolites of flecainide over 48 h was significantly reduced.
These findings suggest that quinidine inhibits the first step of flecainide metabolism, although it may also reduce its renal clearance, but to a lesser extent (3.5 vs 2.9 ml·min−1·kg−1).
The effects of flecainide on ECG intervals were not altered by quinidine.
Thus, quinidine tends to shift extensive metabolizer status for flecainide towards poor metabolizer status and may also alter its renal excretion.
References
The CAST Investigators (1989) Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406–412
Salerno DM, Granrud G, Sharkey P, Krejci J, Larson T, Erlien D, Berry D, Hodges M (1986) Pharmacodynamics and side effect of flecainide acetate. Clin Pharmacol Ther 40:101–107
Eichelbaum M (1988) Genetic polymorphism of sparteine/debrisoquine oxidation. ISI Atlas of Science. Pharmacology 3:243–251
Gross AS, Mikus G, Fischer C, Eichelbaum M (1991) Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. Eur J Clin Pharmacol 40:155–162
Haefeli WE, Bargetzi MJ, Follath F, Meyer UA (1990) Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo. J Cardiovasc Pharmacol 15:776–779
Brøsen K (1990) Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin Pharmacokinet 18:220–239
Mikus G, Gross AS, Beckmann J, Hertrampf R, Gundert-Remy U, Eichelbaum M (1989) The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. Clin Pharmacol Ther 45:562–567
Munafo A, Reymond-Michel G, Biollaz J (1990) Altered flecainide disposition in healthy volunteers taking quinine. Eur J Clin Pharmacol 38:269–273
Brinn R, Brøsen K, Gram LF, Haghfelt T, Otton SV (1986) Sparteine oxidation is practically abolished in quinidine-treatment. Br J Clin Pharmacol 22:194–197
Nielsen MD, Brosen K, Gram LF (1990) A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. Br J Clin Pharmacol 29:299–304
Speirs CJ, Murray S, Boobis AR, Seddon CE, Davies DS (1986) Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolisers of debrisoquine. Br J Clin Pharmacol 22:739–743
Steiner E, Dumont E, Spina E, Dahlqvist R (1988) Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin Pharmacol Ther 43:577–581
Brøsen K, Gram LF (1989) Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. Eur J Clin Pharmacol 37:155–160
Leemann TD, Dayer P, Meyer UA (1986) Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolisers. Eur J Clin Pharmacol 29:739–741
Desmeules J, Gascon M-P, Dayer P, Magistris M (1991) Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 41:23–26
Funck-Brentano C, Turgeon J, Woosley RL, Roden DM (1989) Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. J Pharmacol Exp Ther 249:134–142
Schmid B, Bircher J, Preisig R, Küpfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative Odemethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618–624
Munafo A, Biollaz J (1989) High-performance liquid chromatographic assay with fluorometric detection for flecainide and its major metabolites in urine and serum. J Chromatogr 490:450–457
Hills M, Armitage P (1979) The two-period cross-over clinical trial. Br J Clin Pharmacol 8:7–20
Hedman A, Angelin B, Arvidsson A, Dahlqvist R, Nilsson BS (1990) Interactions in the renal and biliary elimination of digoxin: Stereoselective difference between quinine and quinidine. Clin Pharmacol Ther 47:20–26
Aronson JK, Carver JG (1981) Interaction of digoxin with quinidine. Lancet I:1418
Gross AS, Mikus G, Fischer C, Hertrampf R, Gundert-Remy U, Eichelbaum M (1989) Stereoseletive disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. Br J Clin Pharmacol 28:555–566
Kroemer HK, Turgeon J, Parker RA, Roden DM (1989) Flecainide enantiomers: disposition in human subjects and electrophysiologic actions in vitro. Clin Pharmacol Ther 46:584–590
Conard GJ, Ober RE (1984) Metabolism of flecainide. Am J Cardiol 53:41B-51B
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Munafo, A., Buclin, T., Tuto, D. et al. The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. Eur J Clin Pharmacol 43, 441–443 (1992). https://doi.org/10.1007/BF02220625
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02220625